The Last Peptide Wave Built A $1 Trillion Giant.

RFK Jr. May Have Sparked The Next Wave

May 12, 2026

 *Together with The Precision Peptide Company

The last peptide wave helped create trillion-dollar giants like Eli Lilly and Novo Nordisk.

GLP-1 drugs - Ozempic, Wegovy, Mounjaro, Zepbound - turned peptides into the best-selling drug class in pharma in 2024, overtaking cancer immunotherapies.

Now, a new FDA shift could open the door to an entirely different side of the peptide market.

On April 15, Robert F. Kennedy Jr. announced the FDA would remove 12 peptides from restricted Category 2 status, a move that could rapidly expand mainstream access.

The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) was already positioned before the announcement.

The company is selling products tied to three of the peptides now under review. And while most peptide companies still rely on injections, Precision Peptide has developed a patent-pending transdermal patch for needle-free delivery.

Studies show as many as 63.2% of adults experiencing needle phobia - a major barrier to broader adoption in the peptide market.

With the peptide therapeutics market projected to reach $294 billion by 2033, Precision Peptide is positioned at the forefront of the next evolution in peptide delivery.

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/. NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received six thousand dollars cash (via Think Ink Marketing) for this one day program on 5/12/26 for marketing efforts to increase public awareness of The Precision Peptide Company.  SV may have also previously been compensated for similar marketing efforts. As SV has received compensation from these companies, these parties have financial interests in the securities referenced. Further, SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.